DMXi
About Us
Material Science Microbiology Biochemistry Engineering
DMXi is a Biotechnology start-up launched from the University of Washington's GEMSEC department. A leader in Molecular Biomimetics, our cross disciplinary approach to research and development has led to the discovery and development of an innovative new platform technology derived from the Amelogenin Protein. Our patented sADP5 is a revolutionary new way of approaching the care and treatment of oral care tooth decay which is natural, biological and safe. Researched, developed and commercialized by a team of scientists, clinicians and business entrepreneurs who are all drawn together under the shared goal of putting an end to tooth decay for everyone on the planet.
Dr. Mehmet Sarikaya
Chief Scientific Officer and CEO
Dr. Deniz Yucesoy
Product Development
Dr. Hanson Fong
Lab Operations
Dr. Sami Dogan
Dental Clinician
A message from our founder
Throughout my career, I have been interested in learning lessons from mother nature, in particular, to find how biological hard tissues are formed, with hierarchical structures and multifunctional properties, that are unprecedented in engineered systems. Discovering that it is the proteins that control materials formation in biological systems, our lab GEMSEC (Genetically Engineered Materials Science and Engineering Center) has developed a new field of molecular biomimetics in which genetically designed and engineered solid-binding peptides been used as molecular tool sets in nanotechnology, bionanotechnology, and nanomedicine for the last 20+ years, demonstrated in hundreds of publications in the scientific literature.
Using genetic engineering, molecular biology, machine learning, and materials engineering, the lab developed a patented protocol to derive short peptides from large functional proteins. One of the implementations of this approach has been the design of peptide derived from amelogenin, the major protein in hard tissue formation in human teeth, e.g., enamel (crown of tooth) and cementum (protective cover of the root of tooth). Called ADPs, i.e., amelogenin-derived peptides, the lab has demonstrated in bench tests, animal studies and, most recently, through human efficacy studies that various dental formulations, such as aqueous solutions, tablets, gels, and pastes, can result in the first commercial application of a peptide to guide remineralization of teeth. I am so excited to share this innovation with the world and change the way we think about oral care.
Dr. Mehmet Sarikaya